Table 5.

Effect of CHD in relation to TVOC exposure and serum HCY levels in a stratified analysis of nutrient supplementation

	Folic acid supplementation				Multivitamin supplementation
	Irregularly(N = 51)		Regularly(N = 79)		Irregularly(N = 82)		Regularly(N = 48)
	N, controls/cases	AOR#	N, controls/cases	AOR#	N, controls/cases	AOR#	N, controls/cases	AOR#
Serum Homocysteine
Low(≤ 6.125µmol/L)	21/6	Reference	37/18	Reference	31/15	Reference	27/9	Reference
High(>6.125µmol/L)	9/15	7.65(1.79–32.66)**	10/14	2.90(0.97–8.64)	12/24	3.63(1.33–9.93)*	7/5	3.35(0.70-15.94)
TVOCs
Low(≤ 0.0165 mg/m3)	22/6	Reference	36/6	Reference	33/7	Reference	25/5	Reference
High(>0.0165 mg/m3)	8/15	11.95(2.68–53.39)**	11/26	15.23(4.06–53.70)***	10/32	17.87(5.11–62.53)***	9/9	5.99(1.14–31.49)*

# Adjusted for maternal age, maternal education level, paternal education level, and residence. * Significant differences (p < 0.05) between the low and high groups are indicated. ** Significant differences (p < 0.01) between the low and high groups are indicated. *** Significant differences (p < 0.001) between the low and high groups are indicate